Skip to main content

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Completed · Phase 2 · NCT04921345

Conditions: Moderate-to-Severe Atopic Dermatitis

At a glance

Research payments reported, 2025
$91,145
U.S. investigators named
11
Sites paid
11
Planned or actual enrollment
109

About the trial

Sponsor
Galderma R&D
Tested
Nemolizumab (drug), Nemolizumab (drug)
Dates
Started 2021-06-24; completion 2025-04-28
Results posted
Yes

The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).

From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Galderma Laboratories, L.P. reported $91,145 in research payments for this study in 2025 (47 payments).

Products named: Nemluvio

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Henry Ford Health Hospital, MI $14,542
  • Texas Dermatology and Laser Sp $12,715
  • Arkansas Research Trials Inc $12,411
  • Paddington Testing Company $11,778
  • First Oc Dermatology Research $11,097
  • Regents of the University of California $7,713
  • Pennsylvania State University $6,492
  • Petri $4,760
  • Stringer $3,868
  • Paller $3,570
  • Dawes Fretzin Clinical $2,199

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.